These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 35930260)

  • 1. Long-term management of multiple sclerosis patients treated with cladribine tablets beyond year 4.
    Meuth SG; Bayas A; Kallmann B; Linker R; Rieckmann P; Wattjes MP; Mäurer M; Kleinschnitz C
    Expert Opin Pharmacother; 2022 Sep; 23(13):1503-1510. PubMed ID: 35930260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term management of multiple sclerosis patients treated with cladribine tablets: an expert opinion.
    Meuth SG; Bayas A; Kallmann B; Kleinschnitz C; Linker R; Rieckmann P; Mäurer M
    Expert Opin Pharmacother; 2020 Nov; 21(16):1965-1969. PubMed ID: 32658554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral pulsed therapy of relapsing multiple sclerosis with cladribine tablets - expert opinion on issues in clinical practice.
    Stangel M; Becker V; Elias-Hamp B; Havla J; Grothe C; Pul R; Rau D; Richter S; Schmidt S
    Mult Scler Relat Disord; 2021 Sep; 54():103075. PubMed ID: 34261026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world use of cladribine tablets (completion rates and treatment persistence) in patients with multiple sclerosis in England: The CLARENCE study.
    Brownlee W; Amin A; Ashton L; Herbert A
    Mult Scler Relat Disord; 2023 Nov; 79():104951. PubMed ID: 37639781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and effectiveness of cladribine tablets for multiple sclerosis: Results from a single-center real-world cohort.
    Aerts S; Khan H; Severijns D; Popescu V; Peeters LM; Van Wijmeersch B
    Mult Scler Relat Disord; 2023 Jul; 75():104735. PubMed ID: 37192586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world experience of cladribine treatment in relapsing-remitting multiple sclerosis: A Danish nationwide study.
    Sorensen PS; Pontieri L; Joensen H; Heick A; Rasmussen PV; Schäfer J; Ratzer R; Pihl CE; Sellebjerg F; Magyari M
    Mult Scler Relat Disord; 2023 Feb; 70():104491. PubMed ID: 36623393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cladribine tablets for highly active relapsing-remitting multiple sclerosis in Poland: a real-world, multi-centre, retrospective, cohort study during the COVID-19 pandemic.
    Stępień A; Pogoda-Wesołowska A; Tokarz-Kupczyk E; Słowik A; Puz P; Adamczyk-Sowa M; Kurkowska-Jastrzębska I; Kułakowska A; Chorąży M; Piasecka-Stryczyńska K; Jamróz-Wiśniewska A; Bartosik-Psujek H; Rejdak K
    Neurol Neurochir Pol; 2023; 57(4):371-378. PubMed ID: 37490356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expert opinion on the long-term use of cladribine tablets for multiple sclerosis: Systematic literature review of real-world evidence.
    Oreja-Guevara C; Brownlee W; Celius EG; Centonze D; Giovannoni G; Hodgkinson S; Kleinschnitz C; Havrdova EK; Magyari M; Selchen D; Vermersch P; Wiendl H; Van Wijmeersch B; Salloukh H; Yamout B
    Mult Scler Relat Disord; 2023 Jan; 69():104459. PubMed ID: 36565573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The CLARION study design and status update: a long-term, registry-based study evaluating adverse events of special interest in patients with relapsing multiple sclerosis newly started on cladribine tablets.
    Butzkueven H; Moore N; Aydemir A; Sõnajalg J; Bezemer I; Korhonen P; Sabidó M;
    Curr Med Res Opin; 2022 Jul; 38(7):1167-1176. PubMed ID: 35357268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cladribine tablets : Oral immunotherapy of relapsing-remitting multiple sclerosis with short yearly treatment periods].
    Meuth SG; Ruck T; Aktas O; Hartung HP
    Nervenarzt; 2018 Aug; 89(8):895-907. PubMed ID: 29523912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment satisfaction, safety, and tolerability of cladribine tablets in patients with highly active relapsing multiple sclerosis: CLARIFY-MS study 6-month interim analysis.
    Brochet B; Hupperts R; Langdon D; Solari A; Piehl F; Lechner-Scott J; Montalban X; Selmaj K; Valis M; Rejdak K; Havrdova EK; Patti F; Alexandri N; Nolting A; Keller B
    Mult Scler Relat Disord; 2022 Jan; 57():103385. PubMed ID: 35158476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cladribine tablets in people with relapsing multiple sclerosis: A real-world multicentric study from southeast European MS centers.
    Adamec I; Brecl Jakob G; Rajda C; Drulović J; Radulović L; Bašić Kes V; Lazibat I; Rimac J; Cindrić I; Gržinčić T; Abičić A; Barun B; Gabelić T; Gomezelj S; Mesaroš Š; Pekmezović T; Klivényi P; Krbot Skorić M; Habek M
    J Neuroimmunol; 2023 Sep; 382():578164. PubMed ID: 37536052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment continuation with cladribine at 5 years after initiation in people with multiple sclerosis: A case series and literature review.
    Arun T; Shehu A; Pye E; Smith L; Meehan M
    Mult Scler Relat Disord; 2024 Oct; 90():105837. PubMed ID: 39180839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of therapy satisfaction with cladribine tablets in patients with RMS: Final results of the non-interventional study CLEVER.
    Ziemssen T; Posevitz-Fejfár A; Chudecka A; Cepek L; Reifschneider G; Grothe C; Richter J; Wagner T; Müller B; Penner IK
    Mult Scler Relat Disord; 2024 Oct; 90():105812. PubMed ID: 39151238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of Patient-Reported Outcomes in Patients with Relapsing Multiple Sclerosis Treated with Cladribine Tablets in the CLAWIR Study: 12-Month Interim Analysis.
    Rau D; Müller B; Übler S
    Adv Ther; 2023 Dec; 40(12):5547-5556. PubMed ID: 37776477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An update on cladribine for relapsing-remitting multiple sclerosis.
    Holmøy T; Torkildsen Ø; Myhr KM
    Expert Opin Pharmacother; 2017 Oct; 18(15):1627-1635. PubMed ID: 28858531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunological consequences of cladribine treatment in multiple sclerosis: A real-world study.
    Rolfes L; Pfeuffer S; Huntemann N; Schmidt M; Su C; Skuljec J; Aslan D; Hackert J; Kleinschnitz K; Hagenacker T; Pawlitzki M; Ruck T; Kleinschnitz C; Meuth SG; Pul R
    Mult Scler Relat Disord; 2022 Aug; 64():103931. PubMed ID: 35690010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of cladribine tablets, alemtuzumab, and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England.
    Hettle R; Harty G; Wong SL
    J Med Econ; 2018 Jul; 21(7):676-686. PubMed ID: 29618273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Magnetic Resonance Imaging Evidence Supporting the Efficacy of Cladribine Tablets in the Treatment of Relapsing-Remitting Multiple Sclerosis.
    Cortese R; Testa G; Assogna F; De Stefano N
    CNS Drugs; 2024 Apr; 38(4):267-279. PubMed ID: 38489020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis.
    Comi G; Cook S; Giovannoni G; Rieckmann P; Sørensen PS; Vermersch P; Galazka A; Nolting A; Hicking C; Dangond F
    Mult Scler Relat Disord; 2019 Apr; 29():168-174. PubMed ID: 30885375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.